



EXPRESS MAIL NO.: EV452774245US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robert D'Amato

Confirmation No.: 3798

Application No.: 09/704,054

Group Art Unit: 1614

Filed: November 1, 2000

Examiner: Rebecca Cook

For: METHODS FOR INHIBITION OF
ANGIOGENESIS

Attorney Docket No.: 9516-039-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references C4 - C13 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due.

Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 503013.


Respectfully submitted,

Date January 27, 2005



Yahsir Moon (Reg. No.) 52,042
For: Anthony M. Insogna 35,203
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
9516-039-999APPLICATION NO
09/704,054APPLICANT
D'AmatoFILING DATE
November 11, 2000GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
					<input type="checkbox"/>	<input type="checkbox"/>

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C4	Joseph A. DiPaolo, <i>Cancer Chemotherapy Reports</i> , May 1963, No. 29, p. 99-102, "Effect of Thalidomide on a Variety of Transplantable Tumors"
C5	Joseph A. DiPaolo, <i>Proceedings of the Society for Experimental Biology & Medicine</i> , 1963, v114., pg. 384-387, "In vitro Test Systems for Cancer Chemotherapy, II. Correlation of <i>in vitro</i> Inhibition of Dehydrogenase and Growth with <i>in vivo</i> Inhibition of Ehrlich Asoites Tumor"
C6	Joseph A. DiPaolo, June 26, 1964, "Thalidomide: Effects on Ehrlich Ascites Tumor Cells <i>in vitro</i> "
C7	A. Bach, <i>The Lancet</i> , June 8, 1963, No. 1271, pg. 71, "Thalidomide in Cancer Chemotherapy"
C8	A. Bach, <i>Acta Pathologica Et Microbiologica Scandinavica</i> , 1963 (59), pg. 491-499, "Studies on the Possible Anti-Neoplastic Effect of Thalidomide"
C9	F. J. C. Roe and B. C. V. Mitchley, <i>Nature</i> , December 7, 1963, Volume 200, pg. 1016-17, "Thalidomide and Neoplasia"
C10	Chaundhry, <i>Cancer Research</i> , 1966, 26 part 1, 1884-86, "Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster"
C11	Gershbein, <i>Cancer Letters</i> , 1991, 60: 129-133, "The thalidomide analog, EM 12, Enhances 1,2-Dimethylhydrazine-Induction of Rat Colon Adenocarcinomas,"
C12	Olson et al., <i>Clinical Pharmacology and Therapeutics</i> , 1965, 6(3):292-297, "Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer"
C13	MAU'AD MJ., <i>Anais Paulistas de Medicina e Cirurgia</i> , 1963, 86:13-40, "Clinical Improvements Obtained in Advanced Caner Patients with Treatment with Thalidomide Associated with Hormones"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.